Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

METABOLISM, EXCRETION, AND PHARMACOKINETICS OF DULOXETINE IN HEALTHY HUMAN SUBJECTS

R. J. Lantz, T. A. Gillespie, T. J. Rash, F. Kuo, M. Skinner, H-Y. Kuan and M. P. Knadler
Drug Metabolism and Disposition September 2003, 31 (9) 1142-1150; DOI: https://doi.org/10.1124/dmd.31.9.1142
R. J. Lantz
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. A. Gillespie
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T. J. Rash
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. Kuo
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Skinner
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
H-Y. Kuan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. P. Knadler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Duloxetine is a potent and balanced dual inhibitor of serotonin and norepinephrine reuptake being investigated for the treatment of depression and urinary incontinence. The disposition of duloxetine was studied in four healthy human subjects after a single 20.2-mg (100.6 μCi) oral dose of [14C]duloxetine in an enteric-coated tablet. The mean total recovery of radioactivity (± S.E.M.) after 312 h was 90.5% (±0.4%) with 72.0% (±1.1%) excreted in the urine. Duloxetine was extensively metabolized to numerous metabolites primarily excreted into the urine in the conjugated form. The major biotransformation pathways for duloxetine involved oxidation of the naphthyl ring at either the 4-, 5-, or 6-positions followed by further oxidation, methylation, and/or conjugation. The major metabolites found in plasma were glucuronide conjugates of the following: 4-hydroxy duloxetine (M6), 6-hydroxy-5-methoxy duloxetine (M10), 4, 6-dihydroxy duloxetine (M9), and a sulfate conjugate of 5-hydroxy-6-methoxy duloxetine (M7). The major metabolites found in plasma were also found in the urine, but the urine contained many additional metabolites. In addition to duloxetine, 4-hydroxy duloxetine (M14) and an unidentified polar metabolite were observed in feces. Following [14C]duloxetine administration, Cmax was reached at a median of 6 h for both duloxetine and total radioactivity. Duloxetine accounted for less than 3% of the circulating radioactivity based on mean area under the curve values. The elimination half-life of total radioactivity (120 h) was substantially longer than that of duloxetine (10.3 h).

Footnotes

  • ↵2 Abbreviations used are: 5HT, hydroxytryptamine (serotonin); NE, norepinephrine; LC/MS-MS, liquid chromatography/tandem mass spectrometry; HPLC, high performance liquid chromatography; SPE, solid phase extraction; AUC, area under the curve; amu, atomic mass unit(s).

  • ↵1 Current address: Ligand Pharmaceuticals, 10275 Science Center Drive, San Diego, CA.

    • Received March 10, 2003.
    • Accepted June 6, 2003.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 31 (9)
Drug Metabolism and Disposition
Vol. 31, Issue 9
1 Sep 2003
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
METABOLISM, EXCRETION, AND PHARMACOKINETICS OF DULOXETINE IN HEALTHY HUMAN SUBJECTS
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

METABOLISM, EXCRETION, AND PHARMACOKINETICS OF DULOXETINE IN HEALTHY HUMAN SUBJECTS

R. J. Lantz, T. A. Gillespie, T. J. Rash, F. Kuo, M. Skinner, H-Y. Kuan and M. P. Knadler
Drug Metabolism and Disposition September 1, 2003, 31 (9) 1142-1150; DOI: https://doi.org/10.1124/dmd.31.9.1142

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

METABOLISM, EXCRETION, AND PHARMACOKINETICS OF DULOXETINE IN HEALTHY HUMAN SUBJECTS

R. J. Lantz, T. A. Gillespie, T. J. Rash, F. Kuo, M. Skinner, H-Y. Kuan and M. P. Knadler
Drug Metabolism and Disposition September 1, 2003, 31 (9) 1142-1150; DOI: https://doi.org/10.1124/dmd.31.9.1142
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Humanized PXR-CAR-CYP3A4/7 Mouse as Model of Induction
  • Ozanimod Human Metabolism and Disposition
  • Clearance Pathways: Fevipiprant with Probenecid Perpetrator
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics